IP Library Granted Patent US 10,774,105
Granted Patent B2
US 10,774,105 · App. 16/380,882 · Granted Sep 15, 2020

Phosphoroamidate esters, and use and synthesis thereof

Inventors: Mark Stamatios Kokoris (Bothell, WA); John Tabone (Kirkland, WA); Melud Nabavi (Seattle, WA); Aaron Jacobs (Seattle, WA)
Assignee: STRATOS GENOMICS, INC.
C07H19/10C07F9/65746C07H19/14C07H23/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,774,105
App. No.
16/380,882
Granted
Sep 15, 2020
Kind
B2
Abstract

Phosphoramidate esters and related nucleotide analogs useful in polynucleotide sequencing techniques, and synthetic methods for preparing those compounds, are disclosed, including compounds having the following structure: wherein R 1 , R 2 , R 3 and R 4 are as defined herein. These compounds include nucleotide phosphoramidates analogs that are modified on the alpha-phosphate to enable attachment of a variety of application-specific substituents such as tether molecules.

Claims (21)

1. A compound of the formula:

wherein

R 5 is H;

R 6 is:

7-deaza-9-adeninyl analog of formula

7-deaza-9-guaninyl analog of formula

a 1-uracilyl analog of formula or

a 1-cytosinyl analog of formula

R 8 is —OR 11 ;

R 11 is H; and

R 1 and R 13 are taken together to form a tether segment which allows for linear expansion of the compound upon cleavage of the phosphoramidate bond, wherein the tether is a polymer or a molecular construct having two opposing ends and a generally linear dimension, the ends being attached at the R 1 and R 13 positions by a linkage comprising a triazole group, and wherein the tether segment comprises a reporter construct,

and wherein the compound prior to cleavage of the phosphoramidate bond is in a constrained configuration and upon cleavage of the phosphoramidate bond is in an expanded configuration, such that cleavage of the phosphoramidate bond provides for controlled linear expansion of the compound.

2. The compound of claim 1 wherein R 3 is R 5 .

3. The compound of claim 1 wherein R 3 is

4. The compound of claim 1 wherein R 3 is

5. The compound of claim 1 wherein R 3 is

6. The compound of claim 1 wherein R 3 is

7. The compound of claim 1 wherein R 6 is a 7-deaza-9-adeninyl analog of formula

8. The compound of claim 1 wherein R 6 is an a 7-deaza-9-guaninyl analog of formula

9. The compound of claim 1 wherein R 6 is an a 1-uracilyl analog of formula

10. The compound of claim 1 wherein R 6 is an a 1-cytosinyl analog of formula

Assignments (2)
CHANGE OF NAME Recorded Nov 1, 2023
From: STRATOS GENOMICS, INC.
To: ROCHE DIAGNOSTICS SEATTLE, INC.
Reel/Frame 065419/0739 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2023
From: ROCHE DIAGNOSTICS SEATTLE, INC.
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 065419/0919 →
Continuity (3)
Continuation 14947540 · Nov 20, 2015
Provisional Application 62082488 · Nov 20, 2014
Related Publication 20190330254A1 · Oct 31, 2019
Cited By (2)
US 12,578,321 US 12,625,130